ClinicalTrials.gg
CompletedNCT04912869CROSSWALK-aUpdated Aug 26, 2025

A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Participants With Sickle Cell Disease (SCD).

A Phase 1 interventional study of Crovalimab and Placebo in Sickle Cell Disease, sponsored by Hoffmann-La Roche. Completed at 16 sites in 10 countries. Open to participants aged 12 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-08-26.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
12 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Anemia, Sickle Cell with a site in Spain — 8 open to participants now, 12 under way, 5 of them phase 3. Anemia, Sickle Cell · Spain.

Enrollment
15th of 16
30 · median 161
Started
2022
with 5 others
Phase 1
3 of 23
none open now
Registered
11th of 23
by date
Lead sponsor
2 of 23
Hoffmann-La Roche

Among the 23 studies in Anemia, Sickle Cell with a site in Spain, this one is the 15th largest by enrollment of the 16 interventional ones that give a count, is one of 6 that started in 2022, is one of 3 in phase 1, and was the 11th registered.

Anemia, Sickle Cell

1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

8 of the 23 studies in Anemia, Sickle Cell with a site in Spain are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 12 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Anemia, Sickle Cell with a site in Spain, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate crovalimab for the treatment of a sickle cell pain crisis (also known as a VOE) that requires hospitalisation in adult and adolescent participants with SCD. The primary objective of this study is safety and will additionally evaluate pharmacokinetics (how crovalimab is processed by your body), pharmacodynamics (how your body reacts to crovalimab) and the preliminary efficacy of crovalimab compared with placebo.

03

Conditions studied

  • Sickle Cell Disease

Browse trials for

Keywords

  • Vaso-occlusive episodes
  • Pain crisis
04

Who can participate

Ages eligible
12 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight >=40 kg.
  • Confirmed diagnosis of HbSS (SCD genotype of sickle cell anemia) or HbSβ0 (SCD genotype of sickle cell beta zero thalassemia).
  • Vaccination against Neisseria Meningitidis serotypes A, C, W, and Y.
  • Vaccinations against H. influenzae type B and S. pneumoniae.
  • Participants vaccinated against SARS-CoV-2 are eligible, as long as it has been 3 days or more after inoculation with the vaccine.
  • Diagnosis of an acute uncomplicated VOE, that requires admission to a hospital/acute medical facility and treatment with parenteral opioid analgesics.
  • Adequate hepatic and renal function.
  • >=5 grams/deciliter (g/dL)
  • count >=100,000/microliter (µL)
  • Participants receiving SCD-directed therapies must be on a stable dose for >=28 days.
  • For female participants of , an agreement to remain abstinent or use for 322 days (approximately 10.5 months) after the dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • More than 10 VOEs within the last 12 months prior to presentation, that have required a medical facility visit.
  • Pain related to the current VOE ongoing for >36 hours.
  • Acute pain related to avascular necrosis, hepatic or splenic sequestration, or priapism.
  • Pain atypical of an acute uncomplicated VOE.
  • Evidence of or suspicion of ACS.
  • Evidence or high suspicion of a severe systemic infection.
  • Major surgery and/or hospitalization for any reason within 30 days.
  • History of Neisseria meningitidis infection within 6 months prior.
  • Known infection with a documented \<200 cells/µL.
  • Transfusion or receipt of blood products within 3 months or current participation in a chronic transfusion protocol.
  • Immunized with a within 30 days.
  • History of hematopoietic stem cell transplant.
  • Known or suspected hereditary complement deficiency.
  • Pregnant or breastfeeding, or intending to become pregnant during the study or within 322 days (approximately 10.5 months) after the study drug administration.
  • Participation in another interventional treatment study with an agent or use of any experimental therapy within the prior 28 days or within five half-lives of that investigational product, whichever was greater.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Crovalimab

    Participants will receive a single intravenous (IV) infusion of Crovalimab based on body weight.

    Drug: Crovalimab

  • Placebo comparator
    Placebo

    Participants will receive a single IV infusion of matching Placebo.

    Drug: Placebo

Interventions

  • Crovalimab will be administered as a single dose of 1000 milligrams (mg) IV (for participants with a body weight between 40 kilograms (kg) and 100 kg) or 1500 mg IV (for participants with a body weight \>=100 kg).

  • DrugPlacebo

    Placebo will be administered as a single IV infusion, with an equal volume and over the same duration as weight- based crovalimab

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events (AEs)

    Time frame: Baseline up to Day 84

  2. Percentage of Participants with Infusion-Related Reactions and Hypersensitivity

    Time frame: Baseline up to Day 84

Secondary outcomes

  1. Time to Improvement of the Primary Acute Uncomplicated VOE From Baseline

    Time frame: Baseline up to Day 84

  2. Total Cumulative Opioid Dose From Baseline

    Time frame: Baseline up to Day 84

  3. Time to Discontinuation of all Parenteral Opioids From Baseline

    Time frame: Baseline up to Day 84

  4. Time to Readiness For Hospital Discharge From Baseline

    Time frame: Baseline up to Day 84

  5. Time to Hospital Discharge From Baseline

    Time frame: Baseline up to Day 84

  6. Time to a Confirmed Decrease in Pain Score of at Least 2 Points From the Maximal Pre-dose Pain Score

    Time frame: Baseline up to Day 84

  7. Change in Pain Score From the Maximal Pre-dose Pain Score to the Score at Hospital Discharge

    Time frame: Baseline up to Day 84

  8. Percentage of Participants who Develop Acute Chest Syndrome (ACS)

    Time frame: Baseline up to Day 28

  9. Percentage of Participants Requiring Intensive Care Unit (ICU)/Critical Care Admission for SCD-related Complications

    Time frame: Baseline up to Day 84

  10. Percentage of Participants Requiring Blood Transfusion for SCD-related Complications

    Time frame: Baseline up to Day 84

  11. Readmission Rate for a VOE or VOE-related Event Within 28 days of Discharge of the Primary Acute Uncomplicated VOE

    Time frame: Baseline up to Day 84

  12. Serum Concentrations of Crovalimab Over Time

    Time frame: Baseline up to Day 84

  13. Change in PD Biomarkers Including Complement Activity (CH50) Over Time

    Assessed by a Liposome Immunoassay (LIA)

    Time frame: Baseline up to Day 84

  14. Change Over Time in Free C5 Concentration

    Time frame: Baseline up to Day 84

  15. Change Over Time in Soluble Complement 5b 9 (sC5b-9) Concentration

    Time frame: Baseline up to Day 84

  16. Percentage of Participants with Anti-Drug Antibodies to Crovalimab

    Time frame: Baseline up to Day 84

07

Study locations

16 sites
  • Children'S Healthcare of Atlanta
    Atlanta, Georgia 30329, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Hospital Sao Rafael - HSR
    Salvador, Estado de Bahia 41253-190, Brazil
  • Hospital das Clinicas - UFRGS
    Porto Alegre, Rio Grande do Sul, Brazil
  • CHU Henri Mondor
    Créteil, 64010, France
  • Azienda Ospedaliera di Verona-Policlinico G.B. Rossi
    Verona, Veneto 37134, Italy
  • International Cancer Institute (ICI)
    Eldoret, 30100, Kenya
  • Gertrude's Children Hospital
    Nairobi, Kenya
  • American University of Beirut - Medical Center
    Beirut, 1107 2020, Lebanon
  • Hopital Nini
    Tripoli, Lebanon
  • Amsterdam UMC Location VUMC
    Amsterdam, 1081 HV, Netherlands
  • Charlotte Maxeke Johannesburg Hospital
    Johannesburg, 2193, South Africa
  • Hospital General Univ. Gregorio Maranon
    Madrid, 28009, Spain
  • Hospital Universitario Virgen del Rocio
    Seville, 41013, Spain
  • Hospital Universitario Miguel Servet
    Zaragoza, 50009, Spain
  • Hammersmith Hospital
    London, W12 OHS, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Dec 2024, 32 months.

Of 28 industry-sponsored phase 1 interventional studies under Anemia, Sickle Cell, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's 32 months is above that.

Counting every sponsor, half of 58 studies reached it within 36 months; a quarter within 18 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2021
First posted
Jun 3, 2021
StartActual
Mar 26, 2022
Primary completionActual
Dec 23, 2024
CompletionActual
Aug 15, 2025
Last update
Aug 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04912869
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 3, 2021
Start date
Mar 26, 2022
Primary completion
Dec 23, 2024
Completion
Aug 15, 2025
Last update
Aug 26, 2025

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Crovalimab

Start the discussion